Literature DB >> 12399159

Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro.

Izet M Kapetanovic1, Cynthia D Torchin, John M Strong, Wayne D Yonekawa, Chuang Lu, Albert P Li, Christine M Dieckhaus, Webster L Santos, Timothy L Macdonald, R Duane Sofia, Harvey J Kupferberg.   

Abstract

Antiepileptic therapy with a broad spectrum drug felbamate (FBM) has been limited due to reports of hepatotoxicity and aplastic anemia associated with its use. It was proposed that a bioactivation of FBM leading to formation of alpha,beta-unsaturated aldehyde, atropaldehyde (ATPAL) could be responsible for toxicities associated with the parent drug. Other members of this class of compounds, acrolein and 4-hydroxynonenal (HNE), are known for their reactivity and toxicity. It has been proposed that the bioactivation of FBM to ATPAL proceeds though a more stable cyclized product, 4-hydroxy-5-phenyltetrahydro-1,3-oxazin-2-one (CCMF) whose formation has been shown recently. Aldehyde dehydrogenase (ALDH) and glutathione transferase (GST) are detoxifying enzymes and targets for reactive aldehydes. This study examined effects of ATPAL and its precursor, CCMF on ALDH, GST and cell viability in liver, the target tissue for its metabolism and toxicity. A known toxin, HNE, which is also a substrate for ALDH and GST, was used for comparison. Interspecies difference in metabolism of FBM is well documented, therefore, human tissue was deemed most relevant and used for these studies. ATPAL inhibited ALDH and GST activities and led to a loss of hepatocyte viability. Several fold greater concentrations of CCMF were necessary to demonstrate a similar degree of ALDH inhibition or cytotoxicity as observed with ATPAL. This is consistent with CCMF requiring prior conversion to the more proximate toxin, ATPAL. GSH was shown to protect against ALDH inhibition by ATPAL. In this context, ALDH and GST are detoxifying pathways and their inhibition would lead to an accumulation of reactive species from FBM metabolism and/or metabolism of other endogenous or exogenous compounds and predisposing to or causing toxicity. Therefore, mechanisms of reactive aldehydes toxicity could include direct interaction with critical cellular macromolecules or indirect interference with cellular detoxification mechanisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399159     DOI: 10.1016/s0009-2797(02)00058-3

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  6 in total

1.  N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo.

Authors:  C Charneira; N M Grilo; S A Pereira; A L A Godinho; E C Monteiro; M M Marques; A M M Antunes
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Safety and tolerability of antiepileptic drug treatment in children with epilepsy.

Authors:  Renzo Guerrini; Gaetano Zaccara; Giancarlo la Marca; Anna Rosati
Journal:  Drug Saf       Date:  2012-07-01       Impact factor: 5.606

3.  CPY3A4-mediated α-hydroxyaldehyde formation in saquinavir metabolism.

Authors:  Feng Li; Jie Lu; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2013-11-08       Impact factor: 3.922

4.  Metabolism and Bioactivation of Fluorochloridone, a Novel Selective Herbicide, in Vivo and in Vitro.

Authors:  Jingmin Shi; Cen Xie; Hongbing Liu; Kristopher W Krausz; Carole A Bewley; Suhui Zhang; Liming Tang; Zhijun Zhou; Frank J Gonzalez
Journal:  Environ Sci Technol       Date:  2016-08-05       Impact factor: 9.028

5.  Identification of a metabolic biomarker panel in rats for prediction of acute and idiosyncratic hepatotoxicity.

Authors:  Jinchun Sun; Svetoslav Slavov; Laura K Schnackenberg; Yosuke Ando; James Greenhaw; Xi Yang; William Salminen; Donna L Mendrick; Richard Beger
Journal:  Comput Struct Biotechnol J       Date:  2014-08-09       Impact factor: 7.271

6.  An Atlas of the Quantitative Protein Expression of Anti-Epileptic-Drug Transporters, Metabolizing Enzymes and Tight Junctions at the Blood-Brain Barrier in Epileptic Patients.

Authors:  Risa Sato; Kotaro Ohmori; Mina Umetsu; Masaki Takao; Mitsutoshi Tano; Gerald Grant; Brenda Porter; Anthony Bet; Tetsuya Terasaki; Yasuo Uchida
Journal:  Pharmaceutics       Date:  2021-12-09       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.